Founded in 2018, Aktiia has revolutionized blood pressure monitoring with its CE-marked wristband, the world’s first device capable of providing 24/7 optical blood pressure measurements. This innovative technology, built upon more than two decades of research, offers users personalized, continuous, and medical-grade data on blood pressure and heart rate. The recent funding round, which also saw participation from an international syndicate of investors including Khosla Ventures, Molten, Translink Capital, Verve, and 415 Capital, will enable Aktiia to extend its impactful solution to a broader audience.
Aktiia’s technology has already been embraced by over 60,000 customers and numerous healthcare organizations, with its CE-marked device being approved as a medical device in 44 countries across seven European markets. The company’s expansive dataset, comprising over 300 million data points from users worldwide, continues to grow, offering unparalleled opportunities for deep learning on public health trends and patterns. This vast pool of data is instrumental in advancing the understanding of blood pressure and providing predictive insights on a global scale.
A critical step towards revolutionizing hypertension management
In conjunction with this investment, Aktiia has welcomed Daniel Graf to its board as President. Graf, renowned for his roles at Uber and Google, brings a wealth of experience in scaling innovative technologies. His expertise is expected to be invaluable as Aktiia seeks to broaden its reach and impact in the global healthcare market. CEO Mattia Bertschi expressed pride in Graf’s addition to the team and emphasized the investment as a testament to the partners’ confidence in Aktiia’s technology.
This funding round not only underscores Aktiia’s leadership in the field of blood pressure monitoring but also signifies a critical step towards revolutionizing hypertension management.
